Notice - TEKNOSCAN SYSTEMS INC., H. SAMUEL HYAMS, PHILIP KAI-HING KUNG and SOON FOO (MARTIN) TAM, File No. 2022-19
TORONTO, Jan. 12, 2024 /CNW/ - The previously scheduled days of February 13, 15 and 16, 2024 will not be used for the merits hearing in the above-named matter. The merits hearing will commence on January 29, 2024 and continue on January 30 and 31, February 20, 21, 22, 23, 26, 27, 28 and 29, and April 2, 3, 4, 5, 8 and 9, 2024 at 10:00 a.m. on each day.
The hearing will be held at the offices of the Tribunal at 20 Queen Street West, 17th floor, Toronto. Members of the public may observe the hearing by videoconference, by selecting the "Register to attend" link on the Tribunal's hearing schedule, at capitalmarketstribunal.ca/en/hearing-schedule.
Day 1 of the London Blockchain Conference kicks off today with world-renowned marketing and business entrepreneur and professor Scott Galloway taking the stage.
Tech influencer Lilly Douse will also host this year's conference. She will bring her...
Sungrow, the global leading PV inverter and energy storage system provider, has forged a strategic partnership with Larsen & Toubro to supply 165MW PV inverters and 160MW/760MWh energy storage systems for AMAALA, a prestigious destination in Saudi...
Allied Market Research published a report, titled, "Managed Learning Service Market by Type (Sourcing External Training, L&D Administration, Supplier Management, and Others), Enterprise Size (Small & Medium Enterprises and Large Enterprises),...
Configit, a global leader in Configuration Lifecycle Management (CLM), today announced that Knauf Digital GmbH, a subsidiary of the Knauf Group, has implemented Configit Ace® SaaS to accelerate its Configure, Price, Quote (CPQ) process. Configit's...
Today sees the launch of the Leandro Herrero Institute; a membership community for leaders and professionals who want to directly benefit from Leandro's unique experience, expertise and insights. This was gained from his 25+ years pioneering a better...
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its...
